Skip to main content

Advertisement

Table 1 Variation of glycans determined by lectin microarray analysis of SP cells and MP cells

From: Integrated glycomic analysis of ovarian cancer side population cells

No. Lectin Preferred glycan structure (terminal epitope) SP1 ± SD MP1 ± SD SP1/MP1 SP2 ± SD MP2 ± SD SP2/MP2
1 LTL Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)GlcNAc 0.40 ± 0.02 0.40 ± 0.02 1.00 0.42 ± 0.02 0.45 ± 0.02 0.95
2 PSA Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.78 ± 0.01 0.79 ± 0.06 0.99 0.82 ± 0.04 0.88 ± 0.02 0.93
3 LCA Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.91 ± 0.07 0.84 ± 0.06 1.08 0.89 ± 0.01 0.89 ± 0.03 0.99
4 UEA-I Fuc α1-2(Gal β1-4)GlcNAc 0.41 ± 0.02 0.53 ± 0.03 0.78** 0.60 ± 0.02 0.61 ± 0.01 0.99
5 AOL Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc 0.93 ± 0.34 0.65 ± 0.04 1.43 0.58 ± 0.04 0.55 ± 0.04 1.05
6 AALª Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc (Lex) 1.22 ± 0.09 1.07 ± 0.04 1.14* 0.95 ± 0.05 0.87 ± 0.01 1.10*
7 MALª Sia α2-3Gal β1-4GlcNAc 0.47 ± 0.02 0.60 ± 0.01 0.77*** 0.63 ± 0.02 0.70 ± 0.01 0.90**
8 SNA Sia α2-6Gal/GalNAc 0.82 ± 0.02 1.01 ± 0.05 0.81** 1.03 ± 0.03 0.90 ± 0.03 1.14**
9 SSA Sia α2-6Gal/GalNAc 0.75 ± 0.04 0.90 ± 0.06 0.84* 1.03 ± 0.01 0.92 ± 0.01 1.11***
10 TJA-I Sia α2-6Gal/GalNAc 1.65 ± 0.01 2.28 ± 0.08 0.73*** 1.66 ± 0.15 1.56 ± 0.06 1.06
11 PHA-L Tri/Tetra-antennary complex-type N-glycan 0.45 ± 0.03 0.45 ± 0.01 1.00 0.54 ± 0.01 0.59 ± 0.01 0.91**
12 ECA Gal β1-4GlcNAc 0.86 ± 0.04 0.93 ± 0.04 0.93 1.12 ± 0.04 1.18 ± 0.04 0.95
13 RCA120 Gal β1-4GlcNAc 1.60 ± 0.07 2.43 ± 0.20 0.66** 2.13 ± 0.08 2.25 ± 0.12 0.95
14 PHA-E Complex-type N-glycans with outer Gal and bisecting GlcNAc 0.75 ± 0.05 1.33 ± 0.06 0.57*** 1.01 ± 0.02 0.88 ± 0.05 1.15*
15 DSAª (GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary N-glycans 1.75 ± 0.03 2.21 ± 0.06 0.79*** 1.78 ± 0.04 2.04 ± 0.04 0.87**
16 GSL-II Agalactosylated tri/tetra antennary glycans, GlcNAc 0.48 ± 0.02 0.31 ± 0.00 1.52*** 0.44 ± 0.02 0.43 ± 0.01 1.04
17 NPA High Man, Man α1-6Man 1.52 ± 0.17 1.68 ± 0.03 0.90 1.41 ± 0.04 1.38 ± 0.07 1.02
18 ConA High Man, Man α1-6(Man α1-3)Man (inhibited by presence of bisecting GlcNAc) 2.29 ± 0.23 2.23 ± 0.16 1.03 1.68 ± 0.11 1.59 ± 0.09 1.06
19 GNA High Man, Man α1-3Man 0.98 ± 0.08 1.10 ± 0.01 0.89 1.02 ± 0.02 0.97 ± 0.03 1.05
20 HHL High Man, Man α1-3Man, Man α1-6Man 0.67 ± 0.04 0.58 ± 0.01 1.17* 0.75 ± 0.02 0.74 ± 0.03 1.01
21 ACG Sia α2-3Gal β1-4GlcNAc 1.36 ± 0.18 1.59 ± 0.09 0.85 1.38 ± 0.07 1.57 ± 0.05 0.88*
22 TxLC-I Man3 core, bi- and tri-antennary complex-type N-glycan, GalNAc 1.06 ± 0.04 0.80 ± 0.05 1.32** 0.97 ± 0.05 0.93 ± 0.04 1.04
23 BPL Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc 0.54 ± 0.05 0.53 ± 0.03 1.01 0.66 ± 0.02 0.63 ± 0.02 1.05
24 TJA-II Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreducing terminals 0.92 ± 0.04 1.01 ± 0.02 0.90* 1.11 ± 0.06 1.12 ± 0.03 0.99
25 EEL Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-4GlcNAc 0.58 ± 0.04 0.33 ± 0.02 1.74** 0.51 ± 0.02 0.52 ± 0.01 0.98
26 ABAª Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T 2.16 ± 0.08 0.84 ± 0.06 2.58*** 0.89 ± 0.01 0.84 ± 0.01 1.06*
27 LELª (GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc) 2.39 ± 0.12 2.75 ± 0.16 0.87* 2.95 ± 0.08 3.16 ± 0.09 0.94*
28 STL (GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan backbone) 1.77 ± 0.13 2.19 ± 0.14 0.81* 2.21 ± 0.16 2.36 ± 0.09 0.94
29 UDA GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 1.65 ± 0.16 2.09 ± 0.32 0.79 1.62 ± 0.21 1.94 ± 0.26 0.84
30 PWM (GlcNAc α1-4)n 0.52 ± 0.04 0.58 ± 0.08 0.90 0.82 ± 0.00 0.84 ± 0.03 0.98
31 Jacalin Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 1.51 ± 0.25 1.55 ± 0.15 0.97 1.64 ± 0.04 1.60 ± 0.09 1.02
32 PNAª Gal β1-3GalNAc (α-Thr/Ser (T)) 0.68 ± 0.09 0.36 ± 0.01 1.86** 0.49 ± 0.01 0.43 ± 0.01 1.14**
33 WFA Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)GalNAc 0.52 ± 0.05 0.51 ± 0.02 1.03 0.71 ± 0.08 0.66 ± 0.06 1.08
34 ACA Gal β1-3GalNAc (α-Thr/Ser (T)) 2.20 ± 0.15 1.16 ± 0.14 1.90*** 0.87 ± 0.07 0.97 ± 0.05 0.90
35 MPA Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 0.81 ± 0.08 0.50 ± 0.02 1.61** 0.71 ± 0.04 0.66 ± 0.04 1.08
36 HPA α-Linked terminal GalNAc 0.89 ± 0.04 0.43 ± 0.05 2.08*** 0.45 ± 0.03 0.45 ± 0.02 1.01
37 VVAª α-linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal 0.55 ± 0.03 0.44 ± 0.02 1.24** 0.59 ± 0.03 0.43 ± 0.00 1.35***
38 DBA GalNAc α1-3GalNAc (Blood group A), GalNAc α1-3GalNAc 0.41 ± 0.04 0.34 ± 0.01 1.21* 0.46 ± 0.01 0.46 ± 0.01 1.00
39 SBA α or β-linked terminal GalNAc, GalNAc α1-3Gal 0.56 ± 0.06 0.51 ± 0.05 1.10 0.78 ± 0.04 0.66 ± 0.02 1.18**
40 Calsepaª High Man (Man2-6), N-glycans including bisecting GlcNAc 0.79 ± 0.05 0.66 ± 0.02 1.21* 0.80 ± 0.05 0.67 ± 0.02 1.20*
41 PTL-I α-Linked terminal GalNAc 0.48 ± 0.03 0.53 ± 0.05 0.92 0.59 ± 0.04 0.50 ± 0.02 1.17*
42 MAH Sia α2-3Gal β1-3(Sia α2-6) GalNAc 0.37 ± 0.03 0.49 ± 0.04 0.76* 0.53 ± 0.02 0.50 ± 0.02 1.05
43 WGAª (GlcNAcβ1-4)n, NeuAc, multivalent Sia 1.32 ± 0.09 1.52 ± 0.07 0.87* 1.39 ± 0.02 1.48 ± 0.03 0.93**
44 GSL-IA4 α-GalNAc (α-Thr/Ser (Tn)) 0.53 ± 0.06 0.43 ± 0.03 1.22 0.70 ± 0.01 0.63 ± 0.02 1.11**
45 GSL-IB4ª α-Gal 0.75 ± 0.02 0.55 ± 0.03 1.35*** 0.69 ± 0.01 0.62 ± 0.02 1.11**
  1. aSignificantly changed in two experiments; * p < 0.05; ** p < 0.01; *** p < 0.001